{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:47:50Z","timestamp":1788814070816,"version":"build-2803163510"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770161"],"award-info":[{"award-number":["81770161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The aim of this study was to explore outcomes of planned pregnancy in female patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitors (TKIs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Data of female patients proceeding with a planned pregnancy were retrospectively reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 17 patients with CML who achieved at least a major molecular response (MMR) during imatinib (n = 13) or nilotinib (n = 4) therapy prior to a planned pregnancy were enrolled. At the time of TKI interruption, six were in MMR, two in molecular response 4 (MR4), and nine in molecular response 4.5 (MR4.5). TKI therapy was discontinued 6 weeks (range, 2\u201315 weeks) before conception in 4 patients and at gestational age of 4 weeks (range, 2\u20135 weeks) after determination of pregnancy in 13 patients. Apart from 1 patient who suffered a spontaneous abortion, 16 patients delivered uneventfully. A total of 10 patients lost MMR after stopping TKIs; 8 lost molecular response 2, and 3 lost complete hematological response. Log-rank analyses showed achieving MR4 (p = .030) or MR4.5 (p = .031), complete cytogenetic response duration \u22653.5 years (p = .049), and MMR duration \u22653.5 years (p = .040) were significantly associated with longer MMR-failure-free survival during TKI interruption.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Planned pregnancy might be pragmatic in female patients with CML on TKIs. Achieving deep molecular response and, importantly, MMR duration \u22653.5 years were significantly associated with maintaining MMR during pregnancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Female patients with chronic myeloid leukemia on tyrosine kinase inhibitors (TKIs) wishing to conceive are currently advised to discontinue TKIs before conception. However, the ideal degree and duration of response before stopping TKI, in addition to whether there will be any adverse effect caused by a short exposure of TKI, is unknown. Data of 17 female patients, who achieved at least a major molecular response (MMR) before TKI interruption, was revised, and it was found that achieving deep molecular response and MMR duration \u22653.5 years was significantly associated with maintaining MMR during pregnancy. This provides direct evidence for a planned pregnancy strategy, and stopping TKI immediately after determination of pregnancy in female patients might be pragmatic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0109","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T19:15:14Z","timestamp":1560280514000},"page":"e1141-e1147","source":"Crossref","is-referenced-by-count":19,"title":["Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy"],"prefix":"10.1093","volume":"24","author":[{"given":"Xuelin","family":"Dou","sequence":"first","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhen","family":"Qin","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China"},{"name":"Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"key":"2021122508050105400_onco13011-bib-0001","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2017.77.2574","article-title":"Chronic myelogenous leukemia: Pregnancy in the era of stopping tyrosine kinase inhibitor therapy","volume":"36","author":"Berman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508050105400_onco13011-bib-0002","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.31232","article-title":"Dasatinib dose management for the treatment of chronic myeloid leukemia","volume":"124","author":"Talpaz","year":"2018","journal-title":"Cancer"},{"key":"2021122508050105400_onco13011-bib-0003","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(07)61510-4","article-title":"Chronic myeloid leukaemia in India","volume":"370","author":"Malhotra","year":"2007","journal-title":"Lancet"},{"key":"2021122508050105400_onco13011-bib-0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","article-title":"Chronic myeloid leukemia in Asia","volume":"89","author":"Au","year":"2009","journal-title":"Int J Hematol"},{"issue":"suppl 1","key":"2021122508050105400_onco13011-bib-0005","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1179\/102453312X13336169155772","article-title":"CML treatment in Asia-Pacific region","volume":"17","author":"Jootar","year":"2012","journal-title":"Hematology"},{"key":"2021122508050105400_onco13011-bib-0006","doi-asserted-by":"crossref","first-page":"660","DOI":"10.6004\/jnccn.2018.0035","article-title":"Pregnancy in patients with chronic myeloid leukemia","volume":"16","author":"Berman","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122508050105400_onco13011-bib-0007","first-page":"1505","volume-title":"NCCN guidelines insights: Chronic myeloid leukemia, version 1.2017","author":"Pallera","year":"2016"},{"key":"2021122508050105400_onco13011-bib-0008","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"2021122508050105400_onco13011-bib-0009","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol"},{"key":"2021122508050105400_onco13011-bib-0010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"2021122508050105400_onco13011-bib-0011","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","article-title":"Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?","volume":"37","author":"Qin","year":"2013","journal-title":"Leuk Res"},{"key":"2021122508050105400_onco13011-bib-0012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12288-012-0175-6","article-title":"Physiological changes in hematological parameters during pregnancy","volume":"28","author":"Chandra","year":"2012","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2021122508050105400_onco13011-bib-0013","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"2021122508050105400_onco13011-bib-0014","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2021122508050105400_onco13011-bib-0015","first-page":"22","article-title":"Loss of pregnancy in a patient with chronic myeloid leukemia during treatment with nilotinib","volume":"6","author":"Arnall","year":"2016","journal-title":"J Hematol Oncol Pharm"},{"key":"2021122508050105400_onco13011-bib-0016","article-title":"Delivery of two normal twins exposed to imatinib and nilotinib during the first trimester of pregnancy in a woman with chronic myeloid leukemia","volume":"2","author":"Mseddi","year":"2012","journal-title":"J Hematol Malig"},{"key":"2021122508050105400_onco13011-bib-0017","first-page":"45","article-title":"Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis","volume":"4","author":"Orlandi","year":"2015","journal-title":"Leuk Res Rep"},{"key":"2021122508050105400_onco13011-bib-0018","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/17474086.2018.1500889","article-title":"Chronic myeloid leukemia and pregnancy: Patient and partner perspectives","volume":"11","author":"Luskin","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"2021122508050105400_onco13011-bib-0019","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.13192","article-title":"Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia","volume":"102","author":"Abruzzese","year":"2019","journal-title":"Eur J Haematol"},{"key":"2021122508050105400_onco13011-bib-0020","first-page":"107815521769239","article-title":"Experience with dasatinib and nilotinib use in pregnancy","volume":"24","author":"Barkoulas","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"2021122508050105400_onco13011-bib-0021","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1080\/10428194.2016.1254779","article-title":"CML with pregnancy: Real challenges in developing nations","volume":"58","author":"Sahu","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2021122508050105400_onco13011-bib-0022","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","article-title":"Management of pregnant chronic myeloid leukemia patients","volume":"9","author":"Abruzzese","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"2021122508050105400_onco13011-bib-0023","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol"},{"key":"2021122508050105400_onco13011-bib-0024","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2013-08-283580","article-title":"How I treat leukemia during pregnancy","volume":"123","author":"Milojkovic","year":"2014","journal-title":"Blood"},{"key":"2021122508050105400_onco13011-bib-0025","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome","volume":"7","author":"Apperley","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122508050105400_onco13011-bib-0026","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122508050105400_onco13011-bib-0027","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021122508050105400_onco13011-bib-0028","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"2021122508050105400_onco13011-bib-0029","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V122.21.381.381","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in CP-CML patients who have stopped imatinib after durable undetectable minimal residual disease","volume":"122","author":"Charbonnier","year":"2013","journal-title":"Blood"},{"key":"2021122508050105400_onco13011-bib-0030","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"2021122508050105400_onco13011-bib-0031","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"2021122508050105400_onco13011-bib-0032","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"key":"2021122508050105400_onco13011-bib-0033","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122508050105400_onco13011-bib-0034","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"2021122508050105400_onco13011-bib-0035","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMc0707841","article-title":"Primary ovarian insufficiency associated with imatinib therapy","volume":"358","author":"Christopoulos","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122508050105400_onco13011-bib-0036","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1634\/theoncologist.2011-0137","article-title":"Will imatinib compromise reproductive capacity?","volume":"16","author":"Zamah","year":"2011","journal-title":"The Oncologist"},{"key":"2021122508050105400_onco13011-bib-0037","first-page":"1605","article-title":"Variables associated with patient-reported symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors","volume":"130","author":"Yu","year":"2017","journal-title":"Blood"},{"key":"2021122508050105400_onco13011-bib-0038","first-page":"1809","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Michele","year":"2007","journal-title":"Blood"},{"key":"2021122508050105400_onco13011-bib-0039","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/9781444328332","volume-title":"Hemostasis and Thrombosis in Obstetrics & Gynecology","author":"Paidas","year":"2010"},{"key":"2021122508050105400_onco13011-bib-0040","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Juan Luis","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2021122508050105400_onco13011-bib-0041","author":"FDA","year":"2008"},{"key":"2021122508050105400_onco13011-bib-0042","author":"FDA","year":"2010"},{"key":"2021122508050105400_onco13011-bib-0043","author":"FDA","year":"2010"},{"key":"2021122508050105400_onco13011-bib-0044","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajmg.10781","article-title":"Teratogen-induced limb defects","volume":"112","author":"Holmes","year":"2002","journal-title":"Am J Med Genet"},{"key":"2021122508050105400_onco13011-bib-0045","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122508050105400_onco13011-bib-0046","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/01.AOG.0000465191.27155.25","article-title":"The American College of Obstetricians and Gynecologists practice bulletin no. 150. Early pregnancy loss","volume":"125","author":"Committee on Practice Bulletins\u2014Gynecology","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2021122508050105400_onco13011-bib-0047","doi-asserted-by":"crossref","first-page":"F353","DOI":"10.1136\/fetalneonatal-2011-300631","article-title":"Epidemiology of small intestinal atresia in Europe: A register-based study","volume":"97","author":"Best","year":"2012","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2021122508050105400_onco13011-bib-0048","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/1096-8628(20000828)93:5<355::AID-AJMG3>3.0.CO;2-Q","article-title":"Isolated small intestinal atresias in Latin America and Spain: Epidemiological analysis","volume":"93","author":"Martinez-Frias","year":"2000","journal-title":"Am J Med Genet"},{"key":"2021122508050105400_onco13011-bib-0049","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.puhe.2003.12.017","article-title":"Population-based study of small intestinal atresia and stenosis, Hawaii, 1986-2000","volume":"118","author":"Forrester","year":"2004","journal-title":"Public Health"},{"key":"2021122508050105400_onco13011-bib-0050","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/bdr2.1145","article-title":"Population-based birth defects data in the United States, 2010-2014: A focus on gastrointestinal defects","volume":"109","author":"Lupo","year":"2017","journal-title":"Birth Defects Res"},{"key":"2021122508050105400_onco13011-bib-0051","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2018.027","article-title":"Breastfeeding in patients with chronic myeloid leukaemia: Case series with measurements of drug concentrations in maternal milk and literature review","volume":"10","author":"Chelysheva","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0109","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1141\/41918452\/oncolo_24_11_e1141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1141\/41918452\/oncolo_24_11_e1141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:06:40Z","timestamp":1640419600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/11\/e1141\/6439807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,6,11]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0109","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,6,11]]}}}